At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. We're looking for talented individuals to join us on this exciting journey. Check out our current openings below: https://lnkd.in/gF7-tQhe https://lnkd.in/gTMkN5Gt https://lnkd.in/gHS_JX-x https://lnkd.in/gwGtAm_3 https://lnkd.in/gQ9aBTdB https://lnkd.in/gwss9diN https://lnkd.in/gfgUwNaD https://lnkd.in/gJF8vVMa https://lnkd.in/gAjYbV4P
QurAlis
Biotechnology
Cambridge, MA 8,390 followers
Neuro Pioneers on a Quest to Cure
About us
At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that have the potential to alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative and neurological diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.
- Website
-
https://quralis.com/
External link for QurAlis
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Founded
- 2016
- Specialties
- ALS, FTD, ALS Genes, ALS Drug, Precision Therapy, and Precision Medicine
Locations
-
Primary
100 Cambridge Park Drive
5th Floor
Cambridge, MA 02140, US
Employees at QurAlis
-
Kevin Eggan
-
Anne Whitaker
Independent Director | Private Equity and Board Advisor l Board of Directors Chairwoman l Experienced Biotech CEO and Large Pharma C-Suite Leader
-
Emma Bowden
Vice President, Head of Clinical Development at QurAlis
-
Vikas Sharma
Chief Business Officer @ QurAlis | Entrepreneur | Company builder
Updates
-
QurAlis reposted this
Social Impact Programming and Mission-Driven Culture | Gallery Curator and Creative Strategist | Driving Brand Strength & Community Engagement
Both the arts and sciences thrive on exploration, creativity, the pursuit of knowledge, and a thirst to bring about change. Yesterdays exhibit at Gallery 1832 LabCentral amplified and united the voices of artists and scientists to illuminate these connections. Creativity = Innovation Science + Art = Impact LabCentral #Gallery1832 #ThinkOutsideTheBox 👇
Amazing, inspiring, challenging panel discussion going on at LabCentral on the “Art of the Brain”-with artists Al Weems, Heather Karp, Ibrahim Ali-Salaam and scientists Stefan Irion, Barbara T., Warren Hirst and moderated by Kasper Roet, founder and CEO of QurAlis. We are exploring the intersection of neuroscience, disease, perception of reality altered by disease, coping through communication and art, and science that provides hope to patients and families. Super motivating to keep pushing the science! Thank you Shazia Mir for curating this and our #Gallery1832 ! BlueRock Therapeutics DaCapo Brainscience SV Dementia Discovery Fund (DDF), Bayer
-
-
QurAlis reposted this
Social Impact Programming and Mission-Driven Culture | Gallery Curator and Creative Strategist | Driving Brand Strength & Community Engagement
My soul longs to escape this mental prison placed on me by a brain both broken and beautiful. Fractured yet grounded. Chaotic in the silence. Fearful and yet filled with hope. Forever distorted. Forever beautiful. Yet always me. - Heather Karp (Artist) Last night's art reception and expert panel LabCentral's #Gallery1832 was an inspiring journey into the intersections of #art, #science, and #neurology. We delved into how the human brain perceives reality, especially when altered by neurological diseases, and explored the profound ways art and communication can provide solace and understanding. Our panel of experts moderated by alum Kasper Roet shared groundbreaking insights into the #neuroscience behind conditions that affect perception, such as #Parkinson's, and other neurodegenerative diseases. A key highlight of the evening was the exploration of art as a powerful medium for expression and coping. We heard from #artists and #patients who use creativity as a way to process and express their experiences, offering unique perspectives on their altered realities. These stories underscored the therapeutic power of art, not just for those living with neurological conditions, but also for their families and caregivers. The discussions also brought to light the critical role of science in offering hope. Advances in neuroscience are paving the way for better understanding, diagnosis, and treatment of neurological disorders. The intersection of art and science in this context is particularly compelling, as it combines the emotional and the empirical, providing a holistic approach to care and support. It was a reminder that while these conditions can be daunting, the resilience of the human spirit, combined with scientific innovation, offers hope and inspiration. We are grateful to our panelists, artists, and all attendees for making this event a resounding success. Great to see so many LabCentral alumni! Lets keep pushing the frontiers of science and art to better serve patients and their families. Kasper Roet Barbara T. Warren Hirst Stefan Orion Al Weems Ibrahim Ali-Salaam Heather Karp Johannes Fruehauf QurAlis BlueRock Therapeutics DaCapo Brainscience SV Dementia Discovery Fund (DDF) Bayer
-
-
-
-
-
+2
-
-
QurAlis reposted this
QurAlis' CEO and co-founder Kasper Roet will moderate a panel discussion featuring experts from the realms of neuroscience and R&D, as part of the LabCentral Gallery 1832 latest exhibit exploring the fascinating intersection of art and #neuroscience, 'Art of the Brain: Exploring the Human Experience' taking place this Thursday, July 25, 2024. You can learn more about the event at https://bit.ly/3WzjVtf #precisionmedicine #neurodegenerativediseases #neurologicaldiseases
-
QurAlis' CEO and co-founder Kasper Roet will moderate a panel discussion featuring experts from the realms of neuroscience and R&D, as part of the LabCentral Gallery 1832 latest exhibit exploring the fascinating intersection of art and #neuroscience, 'Art of the Brain: Exploring the Human Experience' taking place this Thursday, July 25, 2024. You can learn more about the event at https://bit.ly/3WzjVtf #precisionmedicine #neurodegenerativediseases #neurologicaldiseases
Gallery 1832 Presents: Art of the Brain - LabCentral | Cambridge, MA
labcentral.org
-
QurAlis reposted this
QurAlis joins the rest of the world today to celebrate inviduals living with #FragileX syndrome (#FXS) and families and friends impacted by FXS, as well as raise awareness as we advance research toward finding effective #precisionmedicine treatments and ultimately a cure. FXS is a rare, genetic #neurologicaldisease that is the leading inherited form of intellectual disability and a known cause of #autism. There are no disease-modifying therapies currently available for FXS. #WorldFragileXDay #NationalFragileXAwarenessDay #NationalFragileXAwarenessMonth
-
-
QurAlis joins the rest of the world today to celebrate inviduals living with #FragileX syndrome (#FXS) and families and friends impacted by FXS, as well as raise awareness as we advance research toward finding effective #precisionmedicine treatments and ultimately a cure. FXS is a rare, genetic #neurologicaldisease that is the leading inherited form of intellectual disability and a known cause of #autism. There are no disease-modifying therapies currently available for FXS. #WorldFragileXDay #NationalFragileXAwarenessDay #NationalFragileXAwarenessMonth
-
-
QurAlis reposted this
The recent FDA approval of #imeltestat is a significant development in #oligonucleotide #therapeutics with many firsts. Imeltestat is the first antagonist, the first N3’-P5’ phosphoramidate backbone chemistry, and the first lipid oligonucleotide conjugate (C16) to be approved in the U.S. C16 conjugates have recently received more attention by companies like Alnylam for the use in their siRNA targeting the #CNS. N3’-P5’ phosphoramidites were introduced by Sergei Gryaznov and coworkers in 1995 and imetelstat (GRN163L) was developed shortly thereafter. It took more than 20 years from lead identification of imeltestat until its FDA approval, but it eventually prevailed. I was privileged to work on this molecule for many years to optimize and scale up the manufacturing process while working at Girindus (now Avecia). Congratulations to the entire imeltestat team for bringing this much-needed new #precisionmedicine to people with MDS.
-
QurAlis reposted this
#ALSNexus is a wrap! QurAlis' CSO Dan Elbaum and Sandy Hinckley, vp and head of discovery, presented and participated in great scientific exchange at the inaugural ALS Nexus Conference. QurAlis is proud to sponsor ALS Nexus as we all work toward making a meaningful difference in the lives of people with #ALS. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases
-
-
#ALSNexus is a wrap! QurAlis' CSO Dan Elbaum and Sandy Hinckley, vp and head of discovery, presented and participated in great scientific exchange at the inaugural ALS Nexus Conference. QurAlis is proud to sponsor ALS Nexus as we all work toward making a meaningful difference in the lives of people with #ALS. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases
-